ReviewEndocrine journal2026
Double faces of pheochromocytoma and paraganglioma-a review of integrated pathologic diagnosis.
Review in Endocrine journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Use of plasma chromogranin a epitopes vasostatin and catestatin as biomarkers for catecholamine-producing tumours in dogs.BMC veterinary research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pheochromocytoma (PCC) and paraganglioma (PGL) are tumors of the adrenal medulla and sympathetic and parasympathetic paraganglia. Both PCC and PGL (PPGLs) are included in neuroendocrine tumors (NETs) of dispersed neuroendocrine system. The most important issue on PPGLs for pathology has been how to differentiate malignant from benign PPGLs, and the previous articles concentrated on solving this difficult issue. However, the concept of PPGLs was dramatically changed by WHO Blue Book, 4th edition (2017), in which all PPGLs have some metastatic potential, therefore, the previous categories of benign and malignant PPGLs have been eliminated in favor of an approach based on risk stratification. This review article includes following issues; 1. historical review of PPGLs, 2. significance of Ki67 labeling index, 3. comparison of scoring system of PASS, GAPP, COPPS these were cited in WHO Tumour Classification 5
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.